Unknown

Dataset Information

0

Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.


ABSTRACT: Allogeneic hematopoietic cell transplantation (alloHCT) for multiple myeloma (MM), with its underlying graft-versus-tumor capacity, is a potentially curative approach for high-risk patients. Relapse is the main cause of treatment failure, but predictors for postrelapse survival are not well characterized. We conducted a retrospective analysis to evaluate predictors for postrelapse overall survival (OS) in 60 MM patients who progressed after myeloablative T cell-depleted alloHCT. The median patient age was 56 years, and 82% had high-risk cytogenetics. Patients received a median of 4 lines of therapy pre-HCT, and 88% achieved at least a partial response (PR) before alloHCT. Of the 38% who received preemptive post-HCT therapy, 13 received donor lymphocyte infusions (DLIs) and 10 received other interventions. Relapse was defined as very early (<6 months; 28%), early (6 to 24 months; 50%), or late (>24 months; 22%). At relapse, 27% presented with extramedullary disease (EMD). The median postrelapse overall survival (OS) by time to relapse was 4 months for the very early relapse group, 17 months for the early relapse group, and 72 months for the late relapse group (P = .002). Older age, relapse with EMD,

SUBMITTER: Gomez-Arteaga A 

PROVIDER: S-EPMC7609585 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4975432 | biostudies-literature
| S-EPMC8945304 | biostudies-literature
| S-EPMC7470026 | biostudies-literature
| S-EPMC7376603 | biostudies-literature
| S-EPMC5988949 | biostudies-literature
| S-EPMC7302932 | biostudies-literature
| S-EPMC5398850 | biostudies-literature
| S-EPMC5826888 | biostudies-literature
| S-EPMC7606268 | biostudies-literature
| S-EPMC5182101 | biostudies-literature